DAL LAB, the smoking cessation MedTech
FR Investor relations

French MedTech · Founded in 2020

Making inhalation medical. Starting with smoking cessation.

DAL LAB is developing the VPM (Medical Personal Vaporiser): a platform for delivering active substances through the lungs in a controlled, reproducible and medically supervised way.

The VPM, DAL LAB's Medical Personal Vaporiser
€4.8M raised since 2020
8.4Mdaily smokers aged 18–75 in France (2024)1
55%of them want to quit smoking1
6–20%of quit attempts lead to abstinence at one year3
68,000premature deaths attributable to tobacco in 20232

The medical need

Most quit attempts fail.

Smoking remains the leading cause of preventable death in France. While more than half of daily smokers want to quit, only a minority of attempts lead to lasting abstinence3.

The literature describes two limitations of current aids: nicotine replacement products that are sometimes under-dosed for highly dependent smokers4, and a gestural and behavioural dimension of dependence that is rarely addressed5.

DAL LAB's programme is designed to meet this need.

Our programme

The VPM: a combination product, medicine and medical device.

A patented technology designed to deliver a controlled dose, without combustion or propellant gas. The VPM is intended for chronic, ambulatory use, with a target cost of around €0.03 per dose to remain affordable.

The cartridge

The medicine

A liquid cartridge containing the active substance, with a calculated and calibrated number of doses. Each active substance is subject to a marketing authorisation held by DAL LAB.

The device

The medical device

A reusable device, targeting CE marking as a Class IIa medical device, with DAL LAB as legal manufacturer.

First indication

Smoking cessation

Controlled nicotine delivery that preserves the hand-to-mouth gesture, within a medical framework. The first building block of a platform that can be extended to other inhaled active substances.

Product under development, not available for sale. The information above describes the programme's objectives and does not constitute efficacy claims.

Progress

Device in validation phase (TRL 5 to 8)
  1. Completed Patents, feasibility studies, scientific advice from the MHRA (UK) and the SMPA (Sweden) 2020–2025
  2. Completed Technical batch: method development January 2026
  3. In progress · 75% Supportive batches: analytical method validation, ageing studies, and extractables and leachables studies Expected completion: January 2027
  4. Upcoming Clinical batch: ageing studies, then clinical study (pharmacokinetics, usability) 2027 · clinical study in November 2027
  5. Target Regulatory validation (targeting CE marking and marketing authorisation) and industrialisation 2029

The smoking cessation market

A global market worth around €25 billion, still largely outside a medical framework.

SMOKERS WORLDWIDE 1.3bn 50–70% of whom want to quit
NICOTINE REPLACEMENT €2.7bn global market in 2023, €3.6bn expected by 2032
E-CIGARETTES €17.7bn global market in 2023, annual growth > 15%

Investor relations

Current funding round: €1.5M

Having raised €4.8M since 2020, DAL LAB is opening a new round to complete clinical trials, finalise the regulatory work and obtain marketing authorisation.

Business model: DAL LAB develops and certifies the VPM platform, then grants exclusive licences by territory (upfront fees, royalties on sales, supply agreements).

Use of funds
R&D and clinical studies · 65%Industrialisation · 15%Regulatory · 20%
  • Shareholders committed since 2020
  • Development and manufacturing partners in place
  • Supported by Agglo du Pays de Dreux and Dev'up Centre-Val de Loire; member of Polepharma and France Biotech
  • Patented technology; scientific advice obtained and ongoing collaboration with the MHRA (UK) and the SMPA (Sweden)

Request the investor pack

Investing in an early-stage company carries a risk of partial or total loss of capital and a risk of illiquidity.

Your data is processed by Dal Lab to respond to your request. Privacy policy

Leadership team

Industrial nicotine expertise, serving a pharmaceutical project.

DAL LAB's leadership team
Portrait of Alexandre Lenormand

Alexandre Lenormand

Chief Executive Officer, co-founder

Engineer, Arts et Métiers ParisTech. Founder of the holding company Schumy Invest, which runs several companies formulating and manufacturing nicotine liquids.

Portrait of David Martin Diaz

David Martin Diaz

Chief Operating Officer, co-founder

COO of Extrapure, a French manufacturer of nicotine bases, and co-founder of Kyado. Business education at EPHEC (Brussels).

Portrait of Léon Chen

Léon Chen

Chief Technology Officer, co-founder

Specialist in compliance and certification of nicotine products. Co-founder of the Neopro laboratory, active in the sector since 2013.

Portrait of Shu Dardenne

Shu Dardenne

Head of Quality Assurance and Regulatory Affairs (QARA)

Degree in pharmacology. Leads quality assurance and regulatory strategy for the VPM (CE marking and marketing authorisation).

Scientific advisory board

Yves Tillet
PharmD, MSc, MBA, FTOPRA. Expert in regulation and assessment of health products

Prof. Daniel Marzin
Toxicology expert, former expert for the French medicines agency (ANSM)

Prof. Philippe Maincent
Expert in pharmaceutical formulation

David Enfrun
ENSAM engineer, expert in medical devices and industrialisation

Jean-Michel Cardot
PharmD, PhD. Expert in biopharmaceutical development

Djakaridia Kouyaté
PhD in chemistry, expert in physical chemistry and analytical methods

Dr Pierre Rouzaud
Physician and toxicologist specialising in tobacco cessation and addiction withdrawal. President of Tabac et Liberté

Dr Marion Adler
Physician specialising in tobacco cessation

Development partners

Meribel PharmaDrug product development (Orléans) and GMP manufacturing (Dreux)
IDDPharmaceutical regulatory affairs (marketing authorisation)
First UnionDevice co-development and manufacturing, ISO 13485
EurofinsBiological evaluation strategy and biocompatibility testing
LMG ConseilEngineering and medical device expertise
Orléans University Hospital (CHU)Clinical trials
Ecosystem and support

A project to bring industry back to a 3,000 m² site in Vernouillet (Eure-et-Loir, France), targeting 120 to 150 jobs by 2033, as part of the national Action Cœur de Ville 2 programme and supported by the City of Vernouillet, Agglo du Pays de Dreux and French government services.

Supported by Agglo du Pays de Dreux logo Agglo du Pays de Dreux Supporting DAL LAB's industrial site project in Vernouillet.
Supported by Dev'up Centre-Val de Loire logo Dev'up Centre-Val de Loire Economic development agency of the Centre-Val de Loire region.
Member Polepharma logo Polepharma Cluster of the French pharmaceutical manufacturing industry.
Member France Biotech logo France Biotech Association of French HealthTech entrepreneurs.

Press releases and media

All press releases
September 2025 · Press release (in French) Dal Lab welcomes two new strategic shareholders Read the press release (PDF) 6 October 2023 · Press release (in French) Positive regulatory meetings with the MHRA and the SMPA on the path to marketing authorisation Read the press release (PDF) 28 January 2022 · Press release (in French) Launch of DAL LAB, the smoking cessation MedTech Read the press release (PDF)
References 1. Santé publique France. Smoking: use, desire to quit and quit attempts. 2024 Health Barometer, published 2025. 2. Santé publique France. Deaths attributable to smoking in France in 2023, published 2026. 3. Tobacco Prevention & Cessation. Factors associated with abstinence after a recent smoking cessation attempt. 4. Trials (BioMed Central), 2020. doi:10.1186/s13063-020-04532-7 5. Sociology of Health & Illness. doi:10.1111/1467-9566.00205

Legal information

Legal notice

Publisher: Dal Lab SAS, a French simplified joint-stock company (société par actions simplifiée) with share capital of €[current capital], registered with the Bobigny Trade and Companies Register under no. 881 728 414. EU VAT no.: FR07881728414. Registered office: 50, rue Bernard, 93000 Bobigny, France. Phone: +33 7 67 81 88 69. Email: contact@dal-lab.tech.

Publishing director: Alexandre Lenormand, President.

Hosting provider: OVH SAS, 2 rue Kellermann, 59100 Roubaix, France. Phone: 1007 (from France).

Intellectual property: all content on this website (text, photographs, visuals, DAL LAB logo) is the property of Dal Lab SAS. Partner logos and trademarks remain the property of their respective owners. Any reproduction without prior authorisation is prohibited.

Regulatory status of the VPM

The VPM is a combination product (medicine and medical device) under development. It does not currently hold a marketing authorisation or CE marking and is not available for sale in any country.

The information on this website presents the company and its research and development programme to investors, partners and professionals. It does not constitute advertising for a medicine or a medical device under the French Public Health Code (articles L.5122-1 and L.5213-1), nor any claim of efficacy or safety, nor medical advice.

If you have questions about quitting smoking, please talk to a healthcare professional or contact your national stop-smoking service (in France: Tabac Info Service, 39 89).

Investor notice

Information about the funding round is provided for information purposes only and does not constitute a public offer of securities or a solicitation to invest. Investing in an unlisted early-stage company carries a risk of partial or total loss of capital, illiquidity and dilution. Any investment decision should be based on a review of the documentation provided by the company and, where appropriate, on independent advice.

Privacy policy (GDPR)

Data controller: Dal Lab SAS, 50, rue Bernard, 93000 Bobigny, France. Contact: contact@dal-lab.tech.

Data collected: through the investor pack form: first name, last name, email address and investor profile; through the newsletter sign-up: email address; by email: the information you send us. No health data is collected on this website.

Purposes and legal bases: responding to your requests and sending you the investor pack (Dal Lab's legitimate interest in responding to requests received); managing relations with investors and partners (legitimate interest); sending the newsletter (consent, which you may withdraw at any time).

Recipients: only authorised Dal Lab staff and its technical service providers acting on its behalf (website hosting). Your data is never sold or transferred. It is hosted in the European Union.

Retention period: 3 years from your last contact with Dal Lab; for the newsletter, until you unsubscribe.

Your rights: you have the right to access, rectify, erase, restrict, object to and port your data, to withdraw your consent, and to give instructions on what happens to your data after your death. To exercise these rights, email contact@dal-lab.tech. You may also lodge a complaint with the French data protection authority, the CNIL (www.cnil.fr).

Cookies: non-essential cookies (in particular audience measurement) are only set with your consent, collected through the cookie banner. You can change your choice at any time; it is kept for a maximum of 6 months.